PuraPly™ Antimicrobial Wound Matrix and Wound Management

Completed

Conditions studied: Pressure Ulcer, Venous Ulcer, Diabetic Ulcer, Surgical Wound, Trauma Wound

In brief

The PuraPly Antimicrobial Wound Matrix (PuraPly AM) case series is a prospective, observational study for patients who have received PuraPly AM which consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) and is intended for the management of wounds; no experimental intervention is involved.

Key facts

Study ID

NCT03070938

Run by

Organogenesis

People needed

100

Starts

2016-11-01

Expected to finish

2017-10-01

Last updated by the study team

2017-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant is at least 18 years of age
• Participant has read, understood and signed and Institutional Review Board (IRB) approved Informed Consent Form (ICF).
• Participant has at least 1 wound appropriate for receiving PuraPly AM, including
• Partial and full-thickness wounds
• Pressure ulcers
• Venous ulcers
• Diabetic ulcers
• Chronic vascular ulcers
• Tunneled/undermined wounds
• Surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) h. Trauma wounds (abrasions, lacerations, second-degree burns, skin tears) i. Draining wounds

You may not qualify if…

• Participant has a known sensitivity to porcine materials
• Participant has a third-degree burn
• Participant has a known sensitivity to polyhexamethylenbiguanide hydrochloride (PHMB)
• Participants receiving concurrent treatment with other topical antimicrobials or skin substitute products

Where it is running

• Winthrop University Hospital — Mineola, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.